Hair loss in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1753-1763

  Patel, Kamal V ^a   Farrant, Paul ^b   Sanderson, Jeremy D ^a   Irving, Peter M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Worthing Hospital   (United Kingdom)

Author keywords

Alopecia; Alopecia areata; Crohn's disease; Hair loss; Inflammatory bowel disease; Telogen affluvium; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; ORAL CONTRACEPTIVE AGENT; RETINOID; SALAZOSULFAPYRIDINE; TIOGUANINE; WARFARIN;

ACUTE DISEASE; ALOPECIA; ALOPECIA AREATA; ALOPECIA TOTALIS; ALOPECIA UNIVERSALIS; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENTERITIS; GENETIC RISK; HAIR LOSS; HUMAN; NUTRITIONAL DEFICIENCY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TELOGEN EFFLUVIUM; ULCERATIVE COLITIS;

ALOPECIA; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 84884150371     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828132de     Document Type: Article

References (104)

1. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol. 2001;15:137-139.
2. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27: 389-395.
3. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999; 341:491-497.
4. th ed. West Sussex, England: Wiley Blackwell; 2001:66.1-66.3.
5. th ed. New York, NY: McGraw-Hill; 2009:962-986.
6. El Shabrawi-Caelen L, La Placa M, Vincenzi C, et al. Adalimumabinduced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis. 2010;16:182-183.
7. McDonagh AJ, Messenger AG. The pathogenesis of alopecia areata. Dermatol Clin. 1996;14:661-670.
8. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc.1995; 70:628-633.
9. Mounsey AL, Reed SW. Diagnosing and treating hair loss. Am Fam Physician. 2009;80:356-362.
10. Schattner A, Shanon Y. Crohn's ileocolitis presenting as chronic diffuse hair loss. J R Soc Med. 1989;82:303-304.
11. Marley J. Inflammatory bowel disease and chronic diffuse hair loss. J R Soc Med. 1989;82:776.
12. Seibold F, Klein R, Jakob F. Polymyositis, alopecia universalis, and primary sclerosing cholangitis in a patient with Crohn's disease. J Clin Gastroenterol. 1996;23:121-124.
13. Tan RS. Ulcerative colitis, myasthenia gravis, atypical lichen planus, alopecia areata, vitiligo. Proc R Soc Med. 1974;67:195-196.
14. Thompson DM, Robinson TW, Lennard-Jones J. Alopecia areata, vitiligo, scleroderma and ulcerative colitis. Proc R Soc Med. 1974; 67:1010-1012.
15. Goddard CJ, August PJ, Whorwell PJ. Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine. Postgrad Med J. 1989;65:188-189.
16. Farshi S, Mansouri P, Safar F, et al. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol. 2010;49:1188-1193.
17. Katsinelos P, Kountouras J, Paroutoglou G, et al. Alopecia areata, primary sclerosing cholangitis, and ulcerative colitis: autoimmunity and apoptosis as common links? Dig Dis Sci. 2007;52:1288-1292.
18. Okan G, Vural P, Peker O, et al. Azathioprine-induced liver injury in a patient with multiple autoimmune syndrome. J Dermatolog Treat. 2010;21:357-360.
19. Sheehan MT, Islam R. Silent thyroiditis, isolated corticotropin deficiency, and alopecia universalis in a patient with ulcerative colitis and elevated levels of plasma factor VIII: an unusual case of autoimmune polyglandular syndrome type 3. Endocr Pract. 2009;15:138-142.
20. Protic M, Gligorijevic V, Bojic D, et al. Autoimmune polyglandular syndrome type 2, alopecia universalis and Crohn's disease. J Crohns Colitis. 2013;7:318-321.
21. Ganzetti G, Campanati A, Offidani A. Alopecia areata: a possible extraintestinal manifestation of Crohn's disease. J Crohns Colitis. 2012;6:962-963.
22. Katsanos K, Christodoulou DK, Stergiopoulou C, et al. Crohn's disease and alopecia areata universalis; case report and review of the literature. Ann Gastroenterol. 2005;18:173-177.
23. Christodoulou DK, Katsanos KH, Kitsanou M, et al. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis. 2002;34:781-786.
24. Snook JA, de Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. Q J Med. 1989;72:835-840.
25. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
26. Muller SA, Winkelmann RK. Alopecia areata. An evaluation of 736 patients. Arch Dermatol. 1963;88:290-297.
27. Thomas EA, Kadyan RS. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol. 2008;53:70-74.
28. Epidemiological evidence of the association between lichen planus and two immune-related diseases. Alopecia areata and ulcerative colitis. Gruppo Italiano Studi Epidemiologici in Dermatologia. Arch Dermatol. 1991;27:688-691.
29. Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65:949-956.
30. Goh C, Finkel M, Christos PJ, et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055-1060.
31. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113-117.
32. Festen EA, Goyette P, Scott R, et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut. 2009;58:799-804.
33. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature. 1996; 379:821-823.
34. Martinez-Mir A, Zlotogorski A, Gordon D, et al. Genome wide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007;80: 316-328.
35. Gregoriou S, Papafragkaki D, Kontochristopoulos G, et al. Cytokines and other mediators in alopecia areata. Mediators Inflamm. 2010;2010: Article ID 928030.
36. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756-1767.
37. Arca E, Musabak U, Akar A, et al. Interferon-gamma in alopecia areata. Eur J Dermatol. 2004;14:33-36.
38. Sato-Kawamura M, Aiba S, Tagami H. Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata. Arch Dermatol Res. 2003;294:536-543.
39. Symington FW. Lymphotoxin, tumor necrosis factor, and gamma interferon are cytostatic for normal human keratinocytes. J Invest Dermatol. 1989;92:798-805.
40. Philpott MP, Sanders DA, Bowen J, et al. Effects of interleukins, colonystimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-α in alopecia areata. Br J Dermatol. 1996;135:942-948.
41. Harrison S, Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009;76:361-367.
42. Wysenbeek AI, Leibovici L, Amit M, et al. Alopecia in systemic lupus erythematosus. Relation to disease manifestations. J Rheumatol. 1991; 18:1185-1186.
43. Electronic Medicines Compendium (eMC website). Available at http://www.medicines.org.uk/emc. Accessed July 1, 2012.
44. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol. 2010;62:191-202.
45. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617-629.
46. Nikfar S, Rahimi R, Rezaie A, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009;54:1157-1170.
47. Netzer P. [Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease]. Schweiz Med Wochenschr. 1995;125:2438-2442.
48. Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988;95:1449-1453.
49. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2008;74:611-613.
50. Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47:850-852.
51. Sood A, Midha V, Sood N, et al. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006; 12:7332-7336.
52. Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005;39:21-26.
53. Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24:1258-1264.
54. Warman JI, Korelitz BI, Fleisher MR, et al. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol. 2003;37:220-225.
55. Ugajin T, Miyatani H, Demitsu T, et al. Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn's disease. Intern Med. 2009;48:693-695.
56. Herrlinger KR, Kreisel W, Schwab M, et al. 6-thioguanine-efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther. 2003; 17:503-508.
57. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2003;18:401-408.
58. Din S, Dahele A, Fennel J, et al. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis. 2008; 14;756-762.
59. Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000; 95:1730-1734.
60. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009;30:614-620.
61. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100-1104.
62. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 2006;54:607-612.
63. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol. 2006;55:632-636.
64. Royer M, Bodemer C, Vabres P, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol. 2011;165: 407-410
65. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
66. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
67. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
68. Lichtenstein GR, Panaccione R, Mallarkey G. Efficacy and safety of adalimumab in Crohn's disease. Therap Adv Gastroenterol. 2008;1:43-50.
69. Russo EA, Harris AW, Campbell S, et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther. 2009;29:308-314.
70. Medkour F, Babai S, Chanteloup E, et al. Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab. Gastroenterol Clin Biol. 2010;34:140-141.
71. Doyle LA, Sperling LC, Baksh S, et al. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-a therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011;33:161-166.
72. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503.
73. Vagianos K, Bector S, McConnell J, et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31: 311-319.
74. Mijac DD, Janković GLJ, Jorga J, et al. Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med. 2010;21:315-319.
75. Han PD, Burke A, Baldassano RN, et al. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:423-443.
76. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002; 27:396-404.
77. Cunningham IJ. The influence of dietary iron on hair and wool growth. NZ J Agric. 1999;44:335-337.
78. Day HG, McCollum EV. Effects of acute dietary zinc deficiency in the rats. Proc Soc Exper Biol Med. 1940;45:282-284.
79. Sullivan M, Nicholls J. Nutritional dermatoses in the rat. IV. Riboflavin deficiency. J Invest Dermatol. 1941;4:181-191.
80. Bradfield RB. Hair tissue in the diagnosis of marasmus and kwashiorkor. J Am Med Womens Assoc. 1973;28:393-394.
81. Bregar RR, Gordon M, Whitney EN. Hair root diameter measurement as an indicator of protein deficiency in nonhospitalized alcoholics. Am J Clin Nutr. 1978;31:230-236.
82. Bradfield RB. Protein deprivation: comparative response of hair roots, serum protein, and urinary nitrogen. Am J Clin Nutr. 1971;24:405-410.
83. Hard S. Non-anemic iron deficiency as an etiologic factor in diffuse loss of hair of the scalp in women. Acta Derm Venereol. 1961;43:562-569.
84. Kantor J, Kessler LJ, Brooks DG, et al. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003;121:985-988.
85. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci. 1992;17:119-123.
86. Rushton DH, Ramsay ID, James KC, et al. Biochemical and trichological characterization of diffuse alopecia in women. Br J Dermatol. 1990;123: 187-197.
87. Deloche C, Bastien P, Chadoutaud S, et al. Low iron stores: a risk factor for excessive hair loss in non-menopausal women. Eur J Dermatol. 2007;17: 507-512.
88. Rushton DH, Norris MJ, Dover R, et al. Causes of hair loss and the developments in hair rejuvenation. Int J Cosmet Sci. 2002;24: 17-23.
89. White MI, Currie J, Williams MP. A study of the tissue iron status of patients with alopecia areata. Br J Dermatol. 1994;130:261-263.
90. Olsen EA, Reed KB, Cacchio PB, et al. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol. 2010;63:991-999.
91. Gonul M, Cakmak SK, Soylu S, et al. Serum vitamin B12, folate, ferritin, and iron levels in Turkish patients with alopecia areata. Indian J Dermatol Venereol Leprol. 2009;75:552.
92. Boffa MJ, Wood P, Griffiths CE. Iron status of patients with alopecia areata. Br J Dermatol. 1995;132:662-664.
93. Shrivastava SB. Diffuse hair loss in an adult female: approach to diagnosis and management. Indian J Dermatol Venereol Leprol. 2009;75:20-27.
94. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54:824-844.
95. Kruis W, Rindfleisch GE, Weinzierl M. Zinc deficiency as a problem in patients with Crohn's disease and fistula formation. Hepatogastroenterology. 1985;32:133-134.
96. Carruthers R. Post-partum alopecia and zinc. Med J Aust. 1983;2:259.
97. Ferrándiz C, Henkes J, Peyrí J, et al. Acquired zinc deficiency syndrome during total parenteral alimentation. Clinical and histopathological findings. Dermatologica. 1981;163:255-266.
98. Alhaj E, Alhaj N, Alhaj NE. Diffuse alopecia in a child due to dietary zinc deficiency. Skinmed. 2007;6:199-200.
99. Bradfield RB. Protein-calorie malnutrition diagnosis by hair tissue: a review. J Trop Pediatr Environ Child Health. 1973;19:370-375.
100. Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:307-320.
101. Nisenson A. Seborrheic dermatitis of infants: treatment with biotin injections for the nursing mother. Pediatrics. 1969;44:1014-1016.
102. Riella MC, Broviac JW, Wells M, et al. Essential fatty acid deficiency in human adults during total parenteral nutrition. Ann Intern Med. 1975;83: 786-789.
103. Kumar V, Kumar M, Yadav M. Alopecia in vitamin D-dependent rickets type II responding to 1a-hydroxycholecalciferol. Ann Trop Paediatr. 2010;30:329-333.
104. Ragunatha S, Inamadar AC, Palit A, et al. Diffuse nonscarring alopecia of scalp: an indicator of early infantile scurvy? Pediatr Dermatol. 2008; 25:644-646.